The PSA test is currently the gold-standard for prostate cancer detection, but is limited for specificity and has limited capacity for prognostic prediction [22]; consequently it cannot readily discriminate patients at higher risk of progressive disease or mortality from those who have a more favorable prognosis. Here, KLK3 is linked to prostate cancer.